# Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

> **NCT00005652** · PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 20 (—)

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT00005652
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2007-08
- **Final completion:** —
- **Target enrollment:** 20 (—)
- **Last updated:** 2008-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005652, "Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00005652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*